Syndivia Presents New DAR1 ADC Data at the Antibody Industrial Symposium

STRASBOURG (France) – June 20, 2024 – Syndivia has released a new poster detailing recent advances with our GeminiMab DAR1 ADC platform, presented at the 12th Antibody Industrial Symposium (AIS) 2024. The work highlights how our hinge-conjugated, site-specific DAR1 architecture improves payload stability and enables predictable high-dose ADC performance across multiple targets.

Our DAR1 ADC approach is designed to reduce hydrophobicity, improve PK, and maintain strong antitumor activity even at lower drug-to-antibody ratios. These features make the GeminiMab platform a compelling option for next-generation ADC development.

For collaboration or licensing discussions, please contact us.